Sequent Scientific Ltd.

Financial

	Sequent Scientific	Unichem Lab	Gufic Biosciences
Operational Metrics
Pharmaceutical Sector
R&D as a % of Total Sales	0.0	7.38 %	0.83 %
Financials
5 yr Average ROE	1.28 %	-2.21 %	25.05 %
5yr average Equity Multiplier	2.12	1.28	2.22
5yr Average Asset Turnover Ratio	0.92	0.42	1.05
5yr Avg Net Profit Margin	0.94 %	-3.85 %	10.9 %
Price to Book	6.65	1.69	5.94
P/E	213.98	30.03	51.25
5yr Avg Cash Conversion Cycle	55.84 Days	80.33 Days	26.94 Days
Inventory Days	76.26 Days	146.44 Days	66.86 Days
Days Receivable	87.51 Days	128.35 Days	128.09 Days
Days Payable	117.98 Days	225.53 Days	163.91 Days
5yr Average Interest Coverage Ratio	2.31	-0.08	13.1
5yr Avg ROCE	7.29 %	-0.47 %	27.25 %
5yr Avg Operating Profit Margin	8.58 %	2.2 %	18.45 %
5 yr average Debt to Equity	0.5	0.09	0.51
5yr CAGR Net Profit	n/a	3.21 %	14.26 %
5yr Average Return on Assets	0.71 %	-1.68 %	11.52 %
Shareholdings
Promoter Holding	52.61 %	70.22 %	72.51 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.41 %	19.29 %	-2.97 %
Change in Mutual Fund Holding (3 Yrs)	9.92 %	1.71 %	2.36 %

Business

	Sequent Scientific	Unichem Lab	Gufic Biosciences
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Product Wise Break-Up	Product Wise Break-Up Formulations 76.31 Active Pharmaceutical Ingredient (API) 21.99 Bulk Drugs and chemicals 0 API 0 Muscle Relaxants 0 Cardiovascular 0 Proton pump inhibitors 0 Anti-fungals 0 Anti-bacterials 0 International 0 CMO 0 Domestic 0 Others 1.7	Product Wise Break-Up Anti-fungals 0 Domestic 0 Bulk Chemicals 8.3 Anti-bacterials 0 Proton pump inhibitors 0 API 0 Formulations 91.7 CMO 0 International 0 Cardiovascular 0 Active Pharmaceutical Ingredient (API) 0 Muscle Relaxants 0	Product Wise Break-Up Anti-fungals 0 Domestic Pharmaceuticals 50.0 Bulk Drugs and chemicals 0 Anti-bacterials 0 Proton pump inhibitors 0 Active Pharmaceutical Ingredient (API) 5.0 Formulations 0 CMO 30.0 International 15.0 Cardiovascular 0 Active Pharmaceutical Ingredient (API) 0 Muscle Relaxants 0
Location Wise Break-Up	Location Wise Break-Up Europe 41.73 Rest of the World 34.17 Asia Pacific 24.1 Turkey 0 LATAM 0 EM 0 USA 0 India 0 South America 0 Australia 0 North America 0 Africa 0	Location Wise Break-Up India 2.47 EM 0 South America 0 North America 0 Asia Pacific 0 Africa 0 USA 60.68 LATAM 0 Turkey 0 Europe 0 Australia 0 Rest of the World 0 Others 36.85	Location Wise Break-Up India 89.07 EM 0 South America 0.23 North America 1.27 Asia Pacific 0 Africa 0.72 USA 0 LATAM 0 Turkey 0 Europe 3.67 Australia 0.53 Rest of the World 0 Others 4.51
Customer Segment	Customer Segment Regulated market 67.0 Less regulated market 33.0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Antibiotic Injectables 33.0 Antibiotic Non-Injectables 15.0 Anthelmintics 11.0 Nutritional 0 Pain management 0 Others 41.0	-	-
R&D Break-Up - Product Wise	R&D Break-Up - Product Wise Formulations 40.0 NiCad 29.0 Patent expiry opportunity 18.0 First generic 9.0 Incremental innovation 4.0	-	-
Dosage Form Break-Up	Dosage Form Break-Up Injectable 55.0 Powder/Premixes 26.0 Solid 6.0 Paste and others 0 Pour on/Spot on 0 Oral Solutions/Suspensions 0 Others 13.0	-	-
Asset Break-Up	Asset Break-Up Asia Pacific 51.03 Europe 24.72 Rest of the World 24.25	-	-
Species Break-Up	Species Break-Up Multispecies 39.0 Ruminants 32.0 Poultry And Poultry Products 12.0 Companion 10.0 Swine 6.0 Others 1.0	-	-

Sequent Scientific Ltd.

SIGN UP FOR FREE